Sign in
TerminatedNo phase

Investigating the Relationship Between Triglycerides and Fetal Overgrowth in Gestational Diabetes

Key facts

Who runs it
University of Kansas Medical Center
Where
Kansas City, United StatesSee the site
Trial code
Status
Terminated
People taking part
7 people enrolled
Started
10 Aug 2023
Ended
1 Sept 2024
Type of study
Observational
Treatments tested
  • Observation
Record updated
20 September 2024
Why it stopped
Unable to recruit subjects

Who can take part

Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • singleton pregnancy
  • diagnosis of GDM between 24-32 weeks
  • BMI >= 30

Who cannot take part

  • autoimmune conditions treated with medication
  • illicit drug use
  • Conditions known to impact fetal growth.These conditions can develop after study enrollment but cannot be present at enrollment
  • chronic hypertension requiring medication
  • fetal genetic conditions
  • preeclampsia
  • fetal growth restriction diagnosis
  • smoking
  • major fetal anomalies

Where in United States

  • University of Kansas Medical CenterKansas City, United States

About the trial

What the trial wants to find out

This is a prospective, observational study which examines the association between maternal triglycerides in the antepartum period and fetal overgrowth in pregnancies complicated by gestational diabetes. Mothers are asked to provide 2 blood samples, undergo fingerstick blood measurements, and to have their newborns measured for body fat composition in the first 6 months of life.

The group in the trial

  • Pregnancies with GDM and BMI > 30

    Pregnancies with GDM diagnosed between 24-32 weeks and BMI \> 30.

    Treatment: Observation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
20 September 2024